TD Asset Management
CLYM

TD Asset Management’s Climb Bio CLYM Stock Holding History

TD Asset Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.48M Buy
267,102
+17,000
+7% +$176K ﹤0.01% 877
2026
Q1 		$1.71M Buy
250,102
+3,902
+2% +$22.5K ﹤0.01% 1002
2025
Q4 		$985K Buy
246,200
+156,800
+175% +$377K ﹤0.01% 1099
2025
Q3 		$180K Hold
89,400
– – ﹤0.01% 1227
2025
Q2 		$111K Hold
89,400
– – ﹤0.01% 1186
2025
Q1 		$109K Hold
89,400
– – ﹤0.01% 1207
2024
Q4 		$161K Hold
89,400
– – ﹤0.01% 1232
2024
Q3 		$445K Buy
+89,400
New +$632K ﹤0.01% 1312

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TD Asset Management's CLYM Position: Q2 2026 in Review

TD Asset Management increased its Climb Bio (CLYM) stake by 6.8% in Q2 2026, buying an estimated $176K and bringing the position to 267,102 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #877.

TD Asset Management first reported a position in CLYM in Q3 2024 and has held it in 8 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • TD Asset Management held 267,102 shares of Climb Bio worth $3.48M as of Q2 2026.
  • TD Asset Management bought 17,000 Climb Bio shares in Q2 2026, an estimated $176K.
  • Climb Bio made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #877 holding.
  • TD Asset Management first reported a position in Climb Bio in Q3 2024 and has held it in 8 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.